Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
Forecasted Federal grant Posted
- Opportunity number
- RFA-CA-26-010
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- Not on record
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Other
- Higher Education Inst. (Public)
- Public or Indian Housing Auth.
- Higher Education Inst. (Private)
- Tribal Organizations (Not Federally Recognized)
- City/Township Governments
- Small Businesses
- County Governments
- Independent School Districts
- State Governments
- 501(c)(3) Nonprofits
- For Profit Organizations
- Special District Governments
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health National Cancer Institute is soliciting applications for the Canine Cancer Immunotherapy Network (K9CIN) cooperative agreement to fund canine clinical trials evaluating immunotherapeutic agents as translatable indicators of safe and effective cancer treatments in humans. This is a reissued opportunity consolidating prior U01 and U24 funding tracks; no specific application deadline appears in the source.
Eligible applicants include higher education institutions (public and private), state and local governments, tribal governments (federally recognized and non-federally recognized), city and county governments, independent school districts, 501(c)(3) and non-501(c)(3) nonprofits, small businesses, for-profit organizations, special district governments, public or Indian housing authorities, faith-based and community-based organizations, regional organizations, U.S. territories and possessions, eligible federal agencies, and non-domestic entities.
The network will consist of five U01 awards: one multifunctional Network Coordinating Center that will facilitate coordination across K9CIN and conduct limited research to support network operations, and four U01 recipients conducting canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities. Pet dog patients develop cancer spontaneously with disease courses and treatment responses similar to those in humans, and immune-intact animals with existing cancers offer the only preclinical means to account comprehensively for all facets of immune response to cancer and therapeutic interventions. Successful canine trials provide translatable data informative to human disease while enabling pet patients to receive cutting-edge therapies.
The program seeks to maintain momentum for development of canine analytics and therapeutics and enable timely evaluation of novel and repurposed drugs, treatment combinations, and dosing and sequencing strategies in pet dogs. Applications fall under CFDA 93.395 (Cancer Treatment Research) and CFDA 93.394 (Cancer Detection and Diagnosis Research). Evaluation criteria assess scientific merit, technical adequacy, investigator competency, facility adequacy, budget justification, and relevance to announced program objectives.
Forecast synopsis
The goal of this RFA is to continue to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. Pet dog patients develop cancer spontaneously and the courses of disease and treatment responses are similar to those in humans. Canine clinical trial results are translatable to humans. The assessment of responses to immunotherapy in immune-intact animals with existing cancers, such as pet dog patients, is the only way to preclinically take into account all facets of the immune response to cancer and to therapies. Ethically, pet dogs can benefit from the clinical trials by receiving cutting-edge therapies supported by the NIH, while providing important data informative to human disease. The network supported by this U01 RFA will consist of five U01 awards. One U01 will serve as a multifunctional Network Coordinating Center that will not only facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN) but will also perform limited research to support the network. Four U01 recipients will conduct canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities.
Through this reissue Notice of Funding Opportunity, the National Cancer Institute intends to continue to support canine immunotherapeutic development as the field continues to grow, in part because of NIH funding. In the last five years, canine immunotherapeutics such as immune checkpoint inhibitors have become available as have canine analytics, development of which were partially supported by NCI. The goal is to maintain the momentum for further development of canine analytics and therapeutics and the ability to evaluate novel and repurposed drugs, treatment combinations, and treatment dosing and sequencing in pet dogs in a timely fashion. This NOFO consolidates the prior U01 (RFA-CA-21-050) and U24 (RFA-CA-21-051) funding opportunities to streamline the application process for continued support to K9CIN. Applicants have the option of submitting either for the Network Coordinating Center with limited research focus or for conducting canine cancer immunotherapy clinical trials and correlative studies. These important canine cancer-related activities will provide a valuable opportunity for NIH support to benefit humans and dogs, at both ends of the leash.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity